Table 1.

Clinical parameters of untreated and ART-treated PLWH study participants

ID	Sex	Agea	CD4 countsb	CD4:CD8 Ratio	Viral loadc	Time since infectiond	ART	Time on ARTd
ART+ #1	M	31	824	0.9	<40	58	Atripla	44
ART+ #2	F	28	535	1.8	<50	177	Viracept Truvada	151
ART+ #3	M	50	569	1.2	<50	111	Darunavir Raltegravir	101
ART+ #4	M	21	796	2.0	<40	8	Stribild	4
ART+ #5	M	50	827	2.3	<40	140	Complera	30
ART+ #6	M	26	331	NA	<40	86	NA	24
ART+ #7	M	42	795	1.1	<40	46	Tivicay/Edurant Viread	33
ART+ #8	M	55	963	1.5	<40	124	Prevista Kivexa Norvir	107
ART- #1	M	40	1,068	1.2	22,812	2	None	NA
ART- #2	M	47	529	1.2	3,189	110	None	NA
ART- #3	M	39	946	0.7	8,809	11	None	NA
ART- #4	M	24	316	0.5	9,496	55	None	NA

N.A, information not available; M, male; F, female.

^aYears.

^bCells/μl.

^cHIV-RNA copies/ml plasma.

^dMonths.